药师干预在骨质疏松症管理中的系统评价
该系统评价检索截至2022年6月的文献,纳入16篇文章(12项研究)、共16307名参与者,评估药师干预对骨质疏松症管理(检查、治疗启动、依从性和患者知识)的效果。药师干预显示对所有结局均有益,但干预异质性和方法学问题限制了结论的可靠性;患者教育与咨询以及药师与医师协作被确定为干预的基石。
要点
- 药师干预可改善骨质疏松症的检查、治疗启动和依从性。
- 患者教育与咨询以及药师-医师协作是干预的基石。
- 干预异质性和方法学问题限制了效果结论的可靠性。
核心结论
- 药师干预在改善骨质疏松症管理方面显示出前景。
- 已识别药师通过开展人群筛查为弥合骨质疏松症治疗差距做出贡献的潜力。
研究设计与样本
- 系统评价,检索PubMed、Embase、国际药学文摘和护理与联合健康文献累积索引,从数据库建库至2022年6月。
- 纳入标准为随机对照试验,研究对象为诊断为骨质疏松症或有骨质疏松症风险的成人,评估药师干预以改善骨质疏松症管理。
- 纳入16篇文章(12项不同的研究),共16307名参与者,发表于2005年至2018年。
- 使用定性分析评估检查、治疗、依从性和患者知识方面的结局,并使用关键评估技能计划清单和Cochrane协作工具(Rob 2.0)评估偏倚风险。
主要发现
- 药师干预分为两类:针对检查与治疗的干预(n=10)和针对依从性的干预(n=2)。
- 针对检查和治疗的干预(n=2)以及针对依从性的干预(n=1)考虑了干预对患者知识的影响。
- 药师干预对所有结局均显示出益处,但干预的异质性和已识别的方法学问题限制了对其实效得出结论的程度。
- 患者教育和咨询被确定为针对检查和治疗以及依从性的药师干预的基石,同时药师与医师协作的重要性也被强调。
局限性
- 干预的异质性限制了对其有效性得出结论的程度。
- 已识别的方法学问题限制了对其有效性得出结论的程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Internationally, there is an osteoporosis treatment gap, which pharmacists may assist in closing. This review identifies pharmacist interventions for improving osteoporosis management and evaluates their effectiveness. Pharmacist interventions are shown to improve osteoporosis management in terms of increasing investigation and treatment commencement and osteoporosis therapy adherence. INTRODUCTION: This review identifies pharmacist interventions for improving osteoporosis management and evaluates their effectiveness. METHODS: A literature search using PubMed, Embase, International Pharmaceutical Abstracts, and Cumulative Index to Nursing and Allied Health Literature was undertaken from database inception to June 2022. Randomised controlled trials were eligible, if they included adults diagnosed with or at risk of osteoporosis and assessed pharmacist interventions to improve osteoporosis management. Outcomes regarding investigation, treatment, adherence and patient knowledge were evaluated using qualitative analysis. The quality of included studies was assessed using the Critical Appraisal Skills Programme checklists and the Cochrane Collaboration tool to assess the risk of bias (Rob 2.0). RESULTS: Sixteen articles (12 different studies) with a total of 16,307 participants, published between 2005 and 2018 were included. Pharmacist interventions were classified into two categories, those targeting investigation and treatment (n = 10) and those targeting adherence (n = 2). The impact of the intervention on patient knowledge was considered by studies targeting both investigation and treatment (n = 2) and adherence (n = 1). Pharmacist interventions demonstrated benefit for all outcomes; however, the extent to which conclusions can be drawn on their effectiveness is limited by the heterogeneity of interventions employed and methodological issues identified. Patient education and counselling were identified as a cornerstone of pharmacist interventions targeting both investigation and treatment and adherence, along with the importance of pharmacist and physician collaboration. CONCLUSION: Pharmacist interventions show promise for improving osteoporosis management. The potential for pharmacists to contribute to closing the osteoporosis treatment gap through undertaking population screening has been identified.
引用
- Laird C, Benson H, Williams KA, et al. Pharmacist interventions in osteoporosis management: a systematic review. Osteoporos Int. 2022. PMID: 36239755. doi:10.1007/s00198-022-06561-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。